"Global Beta-thalassemia (B-thal) Market Overview:
Global Beta-thalassemia (B-thal) Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Beta-thalassemia (B-thal) Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Beta-thalassemia (B-thal) involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Beta-thalassemia (B-thal) Market:
The Beta-thalassemia (B-thal) Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Beta-thalassemia (B-thal) Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Beta-thalassemia (B-thal) Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Beta-thalassemia (B-thal) market has been segmented into:
B-thal
By Application, Beta-thalassemia (B-thal) market has been segmented into:
Iron Chelating Drugs
Erythroid Maturation Agents
Stem Cell Therapy
and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Beta-thalassemia (B-thal) market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Beta-thalassemia (B-thal) market.
Top Key Players Covered in Beta-thalassemia (B-thal) market are:
Celgene Corp.
BlueBird Bio
Protagonist Therapeutics
Agios Pharmaceuticals
Ionis Pharmaceuticals
Vifor Pharma
Orchard Therapeutics
Sangamo Therapeutics
CRISPR Therapeutics
DisperSol Technologies
Kiadis Pharma
Incyte Corporation
Editas Medicine
Global Blood Therapeutics
Syros Pharmaceuticals
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Beta-thalassemia (B-thal) Market by Type
4.1 Beta-thalassemia (B-thal) Market Snapshot and Growth Engine
4.2 Beta-thalassemia (B-thal) Market Overview
4.3 B-thal
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 B-thal: Geographic Segmentation Analysis
Chapter 5: Beta-thalassemia (B-thal) Market by Application
5.1 Beta-thalassemia (B-thal) Market Snapshot and Growth Engine
5.2 Beta-thalassemia (B-thal) Market Overview
5.3 Iron Chelating Drugs
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Iron Chelating Drugs: Geographic Segmentation Analysis
5.4 Erythroid Maturation Agents
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Erythroid Maturation Agents: Geographic Segmentation Analysis
5.5 Stem Cell Therapy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Stem Cell Therapy: Geographic Segmentation Analysis
5.6 and Others
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Beta-thalassemia (B-thal) Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 CELGENE CORP.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BLUEBIRD BIO
6.4 PROTAGONIST THERAPEUTICS
6.5 AGIOS PHARMACEUTICALS
6.6 IONIS PHARMACEUTICALS
6.7 VIFOR PHARMA
6.8 ORCHARD THERAPEUTICS
6.9 SANGAMO THERAPEUTICS
6.10 CRISPR THERAPEUTICS
6.11 DISPERSOL TECHNOLOGIES
6.12 KIADIS PHARMA
6.13 INCYTE CORPORATION
6.14 EDITAS MEDICINE
6.15 GLOBAL BLOOD THERAPEUTICS
6.16 AND SYROS PHARMACEUTICALS
Chapter 7: Global Beta-thalassemia (B-thal) Market By Region
7.1 Overview
7.2. North America Beta-thalassemia (B-thal) Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 B-thal
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Iron Chelating Drugs
7.2.5.2 Erythroid Maturation Agents
7.2.5.3 Stem Cell Therapy
7.2.5.4 and Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Beta-thalassemia (B-thal) Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 B-thal
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Iron Chelating Drugs
7.3.5.2 Erythroid Maturation Agents
7.3.5.3 Stem Cell Therapy
7.3.5.4 and Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Beta-thalassemia (B-thal) Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 B-thal
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Iron Chelating Drugs
7.4.5.2 Erythroid Maturation Agents
7.4.5.3 Stem Cell Therapy
7.4.5.4 and Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Beta-thalassemia (B-thal) Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 B-thal
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Iron Chelating Drugs
7.5.5.2 Erythroid Maturation Agents
7.5.5.3 Stem Cell Therapy
7.5.5.4 and Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Beta-thalassemia (B-thal) Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 B-thal
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Iron Chelating Drugs
7.6.5.2 Erythroid Maturation Agents
7.6.5.3 Stem Cell Therapy
7.6.5.4 and Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Beta-thalassemia (B-thal) Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 B-thal
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Iron Chelating Drugs
7.7.5.2 Erythroid Maturation Agents
7.7.5.3 Stem Cell Therapy
7.7.5.4 and Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Beta-thalassemia (B-thal) Scope:
|
Report Data
|
Beta-thalassemia (B-thal) Market
|
|
Beta-thalassemia (B-thal) Market Size in 2025
|
USD XX million
|
|
Beta-thalassemia (B-thal) CAGR 2025 - 2032
|
XX%
|
|
Beta-thalassemia (B-thal) Base Year
|
2024
|
|
Beta-thalassemia (B-thal) Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals.
|
|
Key Segments
|
By Type
B-thal
By Applications
Iron Chelating Drugs
Erythroid Maturation Agents
Stem Cell Therapy
and Others
|
